In summary, brain metastasis commonly occurring in TNBC and HER2+ BC differ in histopathology and molecular pathway activation which presents an urgent unmet clinical need for more efficacious brain permeable therapeutic strategies. This evidence concerns the gene ERBB2 and breast cancer.